---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-133693"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2024-12-05T23:59:59+00:00"
generated_at: "2026-05-29T07:09:37.982654+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# KalVista Q2 FY2025: No revenue, cash $135.8M; sebetralstat NDA accepted with PDUFA June 17, 2025

## Summary
- R&D expenses $16.6M, G&A $29.2M; pro forma cash $292.2M after $156.4M net November raise.
- FDA accepted NDA for oral on-demand HAE treatment sebetralstat; PDUFA date June 17, 2025.
- MAA submissions in UK, Switzerland, Australia, Singapore via Access Consortium; EMA MAA validated in August.
- Appointed Brian Piekos as CFO; raised $160M total via synthetic royalty financing and equity offerings.
- New data presented at ACAAI and HAEi Global Angioedema Forum supporting early attack treatment and anxiety reduction.

## SEC filing metadata
- accession: 0000950170-24-133693
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2024-12-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017024133693/0000950170-24-133693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017024133693/kalv-20241205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-133693
- JSON: https://secwatch.observer/filing/0000950170-24-133693.json
- Plain text: https://secwatch.observer/filing/0000950170-24-133693.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.